Plateforme Essais de Phase I en Oncologie

Assistant of the university service, she is in charge of the secretariat, of the management of the bibliographical database. She is the link between the clinical, university and analytical teams

Gilles Freyer, Professor of Cancer research in the South Lyon Hospital, is also a doctor in Sciences and graduate of in-depth studies in biological and medical ethics of the university Paris - Necker. Beside his activity in hospital, he leads an activity of research and teaching. As for the research he pilots the trial platform of phase I in cancer research which implies the service of Medical Oncology of the South Lyon Hospital and the team "Modelisation of tumor biology and optimisation cancer drug effects", the constituent of the EA 3738 " Chemotherapy Targeting in Oncology " (director: Pr François-Noël GILLY, UFR Lyon-South Charles Mérieux, UCB Lyon 1). As regards the education, Gilles Freyer teaches the clinical cancer research and the human and social sciences at the University Lyon I. He is the author of various books of whom "Faire face au Cancer: l'espoir au quotidien".

Benoit You is an academic staff physician working within Medical Oncology Department and Onco-Hematology phase 1 trial Unit at Centre Hospitalier Lyon-Sud. He is in charge of the medical oncology trials developed in collaboration with pharmacokinetic-pharmacodynamic laboratory (EA3738) of Faculté de médicine Lyon-Sud Charles Mérieux (Université Claude Bernard Lyon 1).
Graduated from Université Claude Bernard Lyon 1 (France) in 2008, he is a French medical oncologist. He has focused his research activity toward pharmacology (PK-PD), mathematic modeling, tumor marker kinetics and early drug development (phase I and phase II trials). During a 18 month fellowship at Drug Development Program of Princess Margaret Hospital (Toronto, Canada), one of the phase 1 trial centers funded by the US National Cancer Institute, Benoit You improved his skills in phase 1 trial designing and leading. Moreover he established strong collaborations with international collaborative groups including National Cancer Institute of Canada and Gynecology Oncology Group.
He is the first author of 8 pharmacology, modeling or drug development-related articles published in international journals. To lead his research projects, he has received 4 grants or awards including the Bourse Walter-Zelidja from Académie Française and Fellowship award from Ontario Institute for Cancer Research.

Pascal Girard (PhD), INSERM researcher, is a pharmacometrician and an expert in phenomenological modelling and PK-PD population models. He has worked successively with Pr Boissel (IMTh, Lyon) and then as assistant professor at the University of California, San Francisco with Pr Sheiner. During four sabbatical years whilst at Pharsight, he applied his skills to the techniques of stimulation and optimisation of therapeutic trials in the pharmaceutical industry. He is one of the pioneers of modelling compliance to oral treatment.

Benjamin Ribba (PhD), an engineer, trained at Claude Bernard University of Lyon 1, is now a biomathematician having trained in France and studied mathematical modelling of complex systems in cancerology in Israel. He was awarded two international prizes for his theoretical calculations predicting the efficacy of various antineoplastic agents.

Alexandre SOSTELLY got his engineer degree (MEng) in Bio-Informatics and Modelling at the Institut National des Sciences Appliquées of Lyon in 2009 and got the same year a Masters’ degree (MSc) in Pharmacology at the University of Lyon. He is currently a Ph.D. student at the EA3738 and works in collaboration with the Pharmacometrics Research Group at Uppsala University in Sweden (Prof. Mats O. KARLSSON). His research interest focus on inhibition of cancer cells chemoresistance through the development of new efflux transporter inhibitors. It covers modelling of the interaction between these new targeted therapies and cytotoxics in vitro and in vivo, PK-PD and PBPK-PD modelling of the new drugs effect and optimal design for clinical trials in oncology based on tumor growth dynamics.